{"id":"tubocurarine","rwe":[{"pmid":"41671734","year":"2026","title":"Novel short-acting non-depolarizing muscle relaxants derived from galantamine: Design, synthesis, and pharmacological evaluation.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"41207134","year":"2025","title":"Antisense-mediated exon skipping therapy improves neuromuscular junction deficits in a Duchenne muscular dystrophy mouse model.","finding":"","journal":"Neuromuscular disorders : NMD","studyType":"Clinical Study"},{"pmid":"40348092","year":"2025","title":"A peripheral irritant motor response (PIMR) assay to identify chemical-induced locomotor deficits in larval zebrafish (Danio rerio).","finding":"","journal":"Neurotoxicology","studyType":"Clinical Study"},{"pmid":"39944108","year":"2025","title":"An automated platform for simultaneous, longitudinal analysis of engineered neuromuscular tissues for applications in neurotoxin potency testing.","finding":"","journal":"Current research in toxicology","studyType":"Clinical Study"},{"pmid":"30137795","year":"2026","title":"Nondepolarizing Paralytics(Archived).","finding":"","journal":"","studyType":"Clinical Study"}],"_fda":{"id":"28fb3178-9aac-406f-a82a-de53d0876f67","set_id":"11cad8ba-6914-420e-bab0-4ca37d33f2e6","openfda":{"unii":["Q40Q9N063P","2P3VWU3H10","6T6CO7R3Z5","W9FZA51AS1","56K0VVT47P","S003A158SB","01G9XEA93N","79N6542N18","C88X29Y479","E4GA8884NN","I76KB35JEV","ETJ7Z6XBU4","0YPR65R21J","O642E96711","91D9GV0Z28","900961Z8VR"],"route":["ORAL"],"spl_id":["28fb3178-9aac-406f-a82a-de53d0876f67"],"brand_name":["BHI Migraine"],"spl_set_id":["11cad8ba-6914-420e-bab0-4ca37d33f2e6"],"package_ndc":["62795-1019-3"],"product_ndc":["62795-1019"],"generic_name":["ACETIC ACID, ARANEUS DIADEMATUS, ASAFETIDA, BRYONIA ALBA WHOLE, TRIBASIC CALCIUM PHOSPHATE, ACTIVATED CHARCOAL, CINCHONA OFFICINALIS BARK, MARSDENIA CONDURANGO BARK, TUBOCURARINE CHLORIDE, KALMIA LATIFOLIA LEAF, LYCOPODIUM CLAVATUM SPORE, SODIUM SULFATE, PHOSPHORIC ACID, PULSATILLA VULGARIS, CLAVICEPS PURPUREA SCLEROTIUM, AND SILICON DIOXIDE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["ACETIC ACID","ACTIVATED CHARCOAL","ARANEUS DIADEMATUS","ASAFETIDA","BRYONIA ALBA WHOLE","CINCHONA OFFICINALIS BARK","CLAVICEPS PURPUREA SCLEROTIUM","KALMIA LATIFOLIA LEAF","LYCOPODIUM CLAVATUM SPORE","MARSDENIA CONDURANGO BARK","PHOSPHORIC ACID","PULSATILLA VULGARIS","SILICON DIOXIDE","SODIUM SULFATE","STRYCHNINE NITRATE","TRIBASIC CALCIUM PHOSPHATE","TUBOCURARINE CHLORIDE"],"manufacturer_name":["MediNatura Inc"],"is_original_packager":[true]},"purpose":["PURPOSE Migraine Relief Tablets Relieves: • Headache Pain • Headache Pain with Nausea • Neck Muscle Tension"],"version":"5","warnings":["WARNINGS If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If symptoms persist or worsen, a health professional should be consulted. Ask a doctor before use if you have never had migraines diagnosed by a health professional, you have a headache that is different from your usual migraines, you have the worst headache of your life, you have fever and stiff neck, you have a migraine so severe as to require bed rest. Do not use if known sensitivity to BHI Migraine or any of its ingredients exists."],"effective_time":"20230928","active_ingredient":["INGREDIENT SECTIONS Each tablet contains: Aceticum acidum 6X, *Aranea diadema 8X, *Asafoetida 6X, *Bryonia alba 30X, Calcarea phosphorica 10X, *Carbo vegetabilis 10X, *Cinchona officinalis 4X, *Condurango 4X, *Curare 10X, *Kalmia latifolia 8X, *Lycopodium clavatum 6X, Natrum sulphuricum 6X, Phosphoricum acidum 6X, *Pulsatilla 4X, *Secale cornutum 6X, *Silicea 10X, Strychninum nitricum 8X 17.6 mg each. *Natural Ingredients"],"inactive_ingredient":["INACTIVE INGREDIENTS Inactive Ingredients: Dextrose, Magnesium Stearate, Maltodextrin"],"indications_and_usage":["USES For the temporary relief of minor migraine headache pain, headache pain with nausea, headache due to simple nervous tension"],"dosage_and_administration":["DIRECTIONS At first sign of symptoms: Adults: 1 tablet every 1/2 to 1 hour until symptoms lessen, then continue with standard dosage. Standard dosage: Adults: Take 1-2 tablets every 4 to 6 hours. Do not exceed 12 tablets in 24 hours. For children under 18, consult your health professional. Allow tablets to dissolve completely in the mouth, do not swallow."],"spl_product_data_elements":["BHI Migraine ACETIC ACID, ARANEUS DIADEMATUS, ASAFETIDA, BRYONIA ALBA WHOLE, TRIBASIC CALCIUM PHOSPHATE, ACTIVATED CHARCOAL, CINCHONA OFFICINALIS BARK, MARSDENIA CONDURANGO BARK, TUBOCURARINE CHLORIDE, KALMIA LATIFOLIA LEAF, LYCOPODIUM CLAVATUM SPORE, SODIUM SULFATE, PHOSPHORIC ACID, PULSATILLA VULGARIS, CLAVICEPS PURPUREA SCLEROTIUM, and SILICON DIOXIDE ACETIC ACID ACETIC ACID ARANEUS DIADEMATUS ARANEUS DIADEMATUS ASAFETIDA ASAFETIDA BRYONIA ALBA WHOLE BRYONIA ALBA WHOLE TRIBASIC CALCIUM PHOSPHATE CALCIUM CATION ACTIVATED CHARCOAL ACTIVATED CHARCOAL CINCHONA OFFICINALIS BARK CINCHONA OFFICINALIS BARK MARSDENIA CONDURANGO BARK MARSDENIA CONDURANGO BARK TUBOCURARINE CHLORIDE TUBOCURARINE KALMIA LATIFOLIA LEAF KALMIA LATIFOLIA LEAF LYCOPODIUM CLAVATUM SPORE LYCOPODIUM CLAVATUM SPORE SODIUM SULFATE SODIUM SULFATE ANHYDROUS PHOSPHORIC ACID PHOSPHORIC ACID PULSATILLA VULGARIS PULSATILLA VULGARIS CLAVICEPS PURPUREA SCLEROTIUM CLAVICEPS PURPUREA SCLEROTIUM SILICON DIOXIDE SILICON DIOXIDE STRYCHNINE NITRATE STRYCHNINE MAGNESIUM STEARATE MALTODEXTRIN DEXTROSE Leafman"],"keep_out_of_reach_of_children":["KEEP OUT OF REACH OF CHILDREN Keep out of reach of children."],"package_label_principal_display_panel":["Add image transcription here... BHI Migraine Tablet.jpg"]},"tags":[{"label":"tubocurarine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Acetylcholine receptor","category":"target"},{"label":"CHRNA1","category":"gene"},{"label":"CHRNB1","category":"gene"},{"label":"CHRND","category":"gene"},{"label":"M03AA02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Muscle relaxation, function","category":"indication"},{"label":"Bristol Myers Squibb","category":"company"},{"label":"Approved 1940s","category":"decade"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Neuromuscular Agents","category":"pharmacology"},{"label":"Neuromuscular Blocking Agents","category":"pharmacology"},{"label":"Neuromuscular Nondepolarizing Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Nicotinic Antagonists","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG DEPENDENCE","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"ACIDOSIS","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ANAESTHETIC COMPLICATION","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ANAPHYLACTIC SHOCK","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ARRHYTHMIA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BIPOLAR I DISORDER","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BLOOD GLUCOSE ABNORMAL","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BLOOD PRESSURE ABNORMAL","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BODY TEMPERATURE INCREASED","source":"FDA FAERS","actionTaken":"1 reports"}]},"trials":[],"aliases":[],"company":"Bristol-Myers Squibb","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TUBOCURARINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:45:24.640476+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:45:33.595771+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TUBOCURARINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:45:34.361706+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:22.437309+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:45:22.437361+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:45:36.128915+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL339427/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:45:34.958968+00:00"}},"allNames":"dextrotubocurarine chloride","offLabel":[],"synonyms":["tubocurarine","tubocurarine chloride","(+)-Tubocurarine chloride","(+)-Tubocurarine dichloride","D-Tubocurarine","dextrotubocurarine chloride","tubocurarine hydrochloride","tubocurarine HCl"],"timeline":[{"date":"1945-02-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bristol Myers Squibb)"}],"aiSummary":"Dextrotubocurarine Chloride, also known as TUBOCURARINE, is a non-depolarizing neuromuscular blocking agent developed by Bristol Myers Squibb in 1945. It works by competitively binding to the acetylcholine receptor, preventing acetylcholine from binding and causing muscle relaxation. TUBOCURARINE is used to relax muscles and is off-patent, meaning it is no longer protected by patents. As a result, there are no generic manufacturers of the drug. Key safety considerations include its potential to cause respiratory depression and prolonged paralysis.","approvals":[{"date":"1945-02-20","orphan":false,"company":"BRISTOL MYERS SQUIBB","regulator":"FDA"}],"brandName":"Dextrotubocurarine Chloride","ecosystem":[{"indication":"Muscle relaxation, function","otherDrugs":[{"name":"atracurium","slug":"atracurium","company":""},{"name":"cisatracurium","slug":"cisatracurium","company":"Abbvie"},{"name":"dimethyltubocurarinium","slug":"dimethyltubocurarinium","company":"Lilly"},{"name":"doxacurium","slug":"doxacurium","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Acetylcholine receptor","novelty":"First-in-class","targets":[{"gene":"CHRNA1","source":"DrugCentral","target":"Acetylcholine receptor","protein":"Acetylcholine receptor subunit alpha"},{"gene":"CHRNB1","source":"DrugCentral","target":"Acetylcholine receptor","protein":"Acetylcholine receptor subunit beta"},{"gene":"CHRND","source":"DrugCentral","target":"Acetylcholine receptor","protein":"Acetylcholine receptor subunit delta"},{"gene":"CHRNA2","source":"DrugCentral","target":"Neuronal acetylcholine receptor; alpha2/beta2","protein":"Neuronal acetylcholine receptor subunit alpha-2"},{"gene":"CHRNB2","source":"DrugCentral","target":"Neuronal acetylcholine receptor; alpha2/beta2","protein":"Neuronal acetylcholine receptor subunit beta-2"},{"gene":"CHRNG","source":"DrugCentral","target":"Acetylcholine receptor; alpha1/beta1/delta/gamma","protein":"Acetylcholine receptor subunit gamma"},{"gene":"HTR3A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 3A","protein":"5-hydroxytryptamine receptor 3A"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"CHRNA4","source":"DrugCentral","target":"Neuronal acetylcholine receptor; alpha4/beta4","protein":"Neuronal acetylcholine receptor subunit alpha-4"},{"gene":"CHRNB4","source":"DrugCentral","target":"Neuronal acetylcholine receptor; alpha4/beta4","protein":"Neuronal acetylcholine receptor subunit beta-4"}],"modality":"Small Molecule","drugClass":"tubocurarine","explanation":"","oneSentence":"","technicalDetail":"TUBOCURARINE is a competitive antagonist of the nicotinic acetylcholine receptor, specifically targeting the α1, α3, and β1 subunits, which are responsible for the neuromuscular transmission."},"commercial":{"launchDate":"1945","_launchSource":"DrugCentral (FDA 1945-02-20, BRISTOL MYERS SQUIBB)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2781","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TUBOCURARINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T16:10:31.253155","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:45:37.826845+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dimethyltubocurarinium","drugSlug":"dimethyltubocurarinium","fdaApproval":"","relationship":"same-class"}],"genericName":"tubocurarine","indications":{"approved":[{"name":"Muscle relaxation, function","source":"DrugCentral","snomedId":11977004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"dimethyltubocurarinium","brandName":"dimethyltubocurarinium","genericName":"dimethyltubocurarinium","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148050","MMSL":"3097","NDDF":"002399","UNII":"W9YXS298BM","VUID":"4019965","CHEBI":"CHEBI:9774","VANDF":"4017476","RXNORM":"10917","UMLSCUI":"C0041345","chemblId":"CHEMBL339427","ChEMBL_ID":"CHEMBL339427","KEGG_DRUG":"D08655","DRUGBANK_ID":"DB01199","PDB_CHEM_ID":" TC9","PUBCHEM_CID":"6000","SNOMEDCT_US":"25141001","IUPHAR_LIGAND_ID":"2294","SECONDARY_CAS_RN":"6989-98-6","MESH_DESCRIPTOR_UI":"D014403"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1945-","companyName":"Bristol-Myers Squibb","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.0 hours","clearance":"3.4 mL/min/kg","fractionUnbound":"0.58%","volumeOfDistribution":"0.45 L/kg"},"publicationCount":3931,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"M03AA02","allCodes":["M03AA02"]},"biosimilarFilings":[],"originalDeveloper":"Bristol Myers Squibb","recentPublications":[{"date":"2026 Mar","pmid":"41671734","title":"Novel short-acting non-depolarizing muscle relaxants derived from galantamine: Design, synthesis, and pharmacological evaluation.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2025 Nov","pmid":"41207134","title":"Antisense-mediated exon skipping therapy improves neuromuscular junction deficits in a Duchenne muscular dystrophy mouse model.","journal":"Neuromuscular disorders : NMD"},{"date":"2025 May","pmid":"40348092","title":"A peripheral irritant motor response (PIMR) assay to identify chemical-induced locomotor deficits in larval zebrafish (Danio rerio).","journal":"Neurotoxicology"},{"date":"2025","pmid":"39944108","title":"An automated platform for simultaneous, longitudinal analysis of engineered neuromuscular tissues for applications in neurotoxin potency testing.","journal":"Current research in toxicology"},{"date":"2026 Jan","pmid":"30137795","title":"Nondepolarizing Paralytics(Archived).","journal":""}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"1945","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1945-02-20T00:00:00.000Z","mah":"BRISTOL MYERS SQUIBB","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1945-02-20T00:00:00.000Z","mah":"BRISTOL MYERS SQUIBB","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1945-02-20T00:00:00.000Z","mah":"BRISTOL MYERS SQUIBB","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1945-02-20T00:00:00.000Z","mah":"BRISTOL MYERS SQUIBB","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1945-02-20T00:00:00.000Z","mah":"BRISTOL MYERS SQUIBB","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1945-02-20T00:00:00.000Z","mah":"BRISTOL MYERS SQUIBB","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:45:37.826845+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}